Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Immunotherapy
Chase Doyle

Orlando, FL—The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive. According to data presented at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, predictive biomarkers may be close at hand.

Genetic analyses from 2 recent multicohort advanced solid tumor trials suggest that tumor mutational load and tumor T-cell inflammation, measured by gene-expression profiling, are independent determinants of response to anti–PD-1 therapy.

“Nonsynonymous mutational load and neoantigen load, as well as an 18-gene immune-related gene expression profile, were significantly associated with overall response to pembrolizumab across multiple indications. The predicted clinical utility of both mutational load and gene expression profile was similarly high in these cohorts, suggesting comparable individual diagnostic abilities,” said Tanguy Seiwert, MD, Assistant Professor of Medicine, University of Chicago, IL.

“Based on these data, mutational load and gene expression profiling may have utility in characterizing responses to anti–PD-1 and other cancer immunotherapies,” he added.

As Dr Seiwert reported, tumor mutational load has been shown to correlate with benefit from CTLA-4 and PD-1 immunotherapies in multiple tumor types, including melanoma, non–small-cell lung cancer, colorectal cancer, and urothelial cancer. At the same time, tumor T-cell inflammation, which correlates with T-cell infiltration, gamma interferon expression, and PD-L1 and PD-L2 expression, has been advanced as an alternative biomarker.

Using data from 2 multicenter, multicohort studies (KEYNOTE-012 and KEYNOTE-028), Dr Seiwert and colleagues examined the association between mutational load and progression-free survival in 153 patients with PD-L1–positive tumors—21 different tumor types—who had whole-exome sequencing available. Overall response was also evaluated in patients with whole-exome sequencing and measurable disease at baseline (n = 135). For tumor T-cell inflammation, expression values for 18 genes were used to determine whether the tumor was inflamed. Finally, the association between mutational load and gene-expression profiling was also explored in Moffitt and The Cancer Genome Atlas data sets.

According to Dr Seiwert, objective response to treatment was significantly associated with mutational load (P = .0001), neoepitope load (P = .0001), and gene-expression profile (P = .0004). More specifically, at a mutational load cutoff of 102, response rates exceeded 30% in patients with ≥102 mutations. For patients with tumors carrying <102 mutations, however, response rates dropped to 7%.

Gene-expression profiling was also significantly associated with overall survival (P = .0071). In addition, patients with more inflamed tumors had a response rate of 25%, compared with a response rate of only 2% for patients with noninflamed tumors.

Finally, in patients with high mutational load and tumor inflammation, response rates exceeded 38%. In patients with low mutational load and noninflamed tumors, however, response rates fell to 0%.

“Mutational load and tumor T-cell inflammation are common features of anti–PD-1 responsive tumors. Whether used separately or in combination, these markers appear to have a high positive and negative predictive value, and may have clinical utility,” Dr Seiwert concluded.

Related Items
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Immunotherapy, Online First
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Multiple Myeloma
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA 2017 Highlights
Prescription Drug Use High Among Survivors of Childhood Cancers
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Survivorship
Shared Antigens Yield Promising Targets for Cancer Prevention
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Immunotherapy
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Immunotherapy
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA 2017 Highlights
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA 2017 Highlights
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA 2017 Highlights
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA 2017 Highlights
Last modified: May 10, 2017